Dmitry Balyasny’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Dmitry Balyasny’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-200,000	Closed	-$200K	–	2527
2021 Q2	$200K	Buy	200,000 +111,434	+126%	+$90.1K	﹤0.01%	1730
2021 Q1	$54K	Buy	+88,566	New	+$85.5K	﹤0.01%	1681

Other funds holding EFTRW

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Dmitry Balyasny's EFTRW Position: Q3 2021 in Review

Dmitry Balyasny sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2021, closing a stake of 200,000 shares — an estimated $200K sold.

Dmitry Balyasny first reported a position in EFTRW in Q1 2021 and held it in 2 quarters. The position peaked at $200K in Q2 2021. 21 funds tracked by Wall St. Rank hold EFTRW as of Q3 2021.

Dmitry Balyasny reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
Dmitry Balyasny sold 200,000 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $200K.
Dmitry Balyasny first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 2 quarters.
Dmitry Balyasny's eFFECTOR Therapeutics, Inc. Warrant position peaked at $200K in Q2 2021.
21 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.